Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 1.51 EUR -1.56% Market Closed
Market Cap: 96.3m EUR
Have any thoughts about
Oryzon Genomics SA?
Write Note

Oryzon Genomics SA
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Oryzon Genomics SA
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Oryzon Genomics SA
MAD:ORY
Cash Interest Paid
€397.1k
CAGR 3-Years
17%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Grifols SA
MAD:GRF
Cash Interest Paid
€528.9m
CAGR 3-Years
50%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Pharma Mar SA
MAD:PHM
Cash Interest Paid
€2.4m
CAGR 3-Years
-5%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Biotechnology Assets SA
MAD:BST
Cash Interest Paid
€44k
CAGR 3-Years
N/A
CAGR 5-Years
-49%
CAGR 10-Years
N/A
No Stocks Found

Oryzon Genomics SA
Glance View

Market Cap
95m EUR
Industry
Biotechnology

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

ORY Intrinsic Value
1.45 EUR
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Oryzon Genomics SA's Cash Interest Paid?
Cash Interest Paid
397.1k EUR

Based on the financial report for Dec 31, 2023, Oryzon Genomics SA's Cash Interest Paid amounts to 397.1k EUR.

What is Oryzon Genomics SA's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
-2%

Over the last year, the Cash Interest Paid growth was 25%. The average annual Cash Interest Paid growth rates for Oryzon Genomics SA have been 17% over the past three years , -2% over the past five years .

Back to Top